リチウム療法を受けている患者におけるCOVID-19感染が腎機能に及ぼす影響を調査するためのNational COVID cohort collaborative (N3C)データの使用

Lithium is a drug primarily used to treat psychiatric disorders and has shown significant efficacy in treating bipolar disorder (BD) and major depressive disorder (MDD). Although lithium can stabilize emotional fluctuations and prevent the onset of depressive and manic episodes, case reports of patients treated with lithium developing kidney dysfunction after being infected with SARS-CoV-2 emerged during the COVID-19 pandemic. We used the National COVID Cohort Collaborative (N3C) dataset to investigate the relationship between patients with lithium exposure and with SAR-Co-V-2 infection, and kidney dysfunction. Using data from March 1, 2021, to September 30, 2022, patients were classified as whether they were infected with SARS-CoV-2. We used the estimated glomerular filtration rate (eGFR) to observe whether there are significant differences between the two groups. Our findings suggest that the impact of lithium treatment and COVID-19 on kidney function may not be significant, consistent with most other studies' findings.